Skip to content

Lorazepam for Delirium Prevention in Critically Ill Patients With High Anttila-Index

Preventive Administration of Lorazepam in Critically Ill Patients With High Anttila-Index to Reduce the Incidence of Intensive Care Delirium: a Single-centre, Randomized, Controlled Clinical Trial - the Basel LOC2DEL-Trial

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07428681
Acronym
LOC2DEL
Enrollment
260
Registered
2026-02-24
Start date
2027-03-01
Completion date
2029-02-01
Last updated
2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium Confusional State

Brief summary

Delirium is a neuropsychiatric syndrome characterized by cognitive and attentional deficits, circadian rhythm, emotional and psychomotor dysregulation. It is frequently encountered in patients admitted to an Intensive Care Unit (ICU) with a prevalence of 20-80% and associated with higher morbidity and mortality, prolonged hospitalization and cognitive impairment after hospitalization. Alcoholism is an important risk factor that favors the development of delirium and a common comorbidity in patients admitted to the ICU. Patients with alcohol use disorders can develop a withdrawal syndrome after cessation of alcohol consumption. The most severe form of alcohol withdrawal is the alcohol withdrawal delirium, which is characterized by a profound state of confusion. Early recognition and treatment significantly diminish severe complications of alcohol withdrawal delirium, including mortality. The common pharmacological prevention and therapy of alcohol withdrawal syndrome is the administration of benzodiazepines, which have the potential to prevent or mitigate alcohol withdrawal delirium. In the ICU setting the diagnosis of alcoholism based on self-report can be unreliable and complicated by acute illness. The Anttila-Index is a parameter calculated from the carbohydrate-deficient transferrin and the gamma-glutamyltransferase. It has a high sensitivity and specificity for excessive alcohol consumption. Therefore, the Anttila-Index of patients admitted to the ICU could help identify patients at risk for developing delirium due to alcoholism or due to alcoholism in combination with other risk factors. Schreiber et al. recently (October 2023) found significantly higher Anttila-Index in patients with delirium on a medical ICU. The investigators postulate that this also applies to the patients admitted to the mixed (medical and surgical) ICU at the University Hospital Basel (USB), since surgery is an additional crucial risk factor for delirium development. Hypothesis: ICU delirium can be reduced by careful preventive administration of lorazepam in patients admitted to the ICU with an Anttila-Index at or above the cutoff value of four.

Interventions

0.5-1mg intravenously administered every 6 hours for 3 days

DRUGPlacebo

same amount (ml) of an identical viscous, oily solution without any pharmacological activity intravenously administered every 6 hours for 3 days

Sponsors

University Hospital, Basel, Switzerland
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Emergency/unplanned admission to the ICU * Age ≥ 18 years * ICU stay ≤ 24 hours until first study intervention * Hospital admission ≤ 24 hours before ICU admission * Anttila-Index ≥ 4

Exclusion criteria

* Pre-existing delirium * Admission diagnosis that requires the administration of benzodiazepines (e.g. epileptic seizure) * Pre-existing therapy with benzodiazepines * Women: Pregnancy or breastfeeding * Sequelae of acute intoxication (drugs or alcohol) at time of inclusion * Hypersensitivity, allergy, or other absolute contraindication to lorazepam * Participation in another study with investigational drug within the 30 days preceding and during the present study

Design outcomes

Primary

MeasureTime frame
Incidence of ICU delirium (yes/no)until day 3 after first study intervention

Contacts

CONTACTProf. Dr. med. M. Siegemund, MD
martin.siegemund@usb.ch+41(0)613286414
CONTACTPD Dr. med. A. Hollinger, MD

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026